MALDI Imaging of predictive ferritin, fibrinogen and proteases in haemophilic arthropathy

Haemophilia

Volumn 20, Issue 3, 2014, Pages 446-453

  Kriegsmann, M ^a   Casadonte, R ^b   Randau, T ^c   Gravius, S ^c   Pennekamp, P ^c   Strauss, A ^c   Oldenburg, J ^c   Wieczorek, K ^a   Deininger, S O ^d   Otto, M ^b   Kriegsmann, J ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Institute of Molecular Pathology   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d BRUKER DALTONIK GMBH   (Germany)

Author keywords

Haemophilia; Haemophilic arthritis; Haemophilic arthropathy; IMS; MALDI; Mass spectrometry

Indexed keywords

BLOOD CLOTTING FACTOR 8; FERRITIN; FIBRINOGEN; FORMALDEHYDE; HEMOGLOBIN; LIPOCORTIN 2; PARAFFIN; PROTEINASE; PEPTIDE HYDROLASE;

ARTICLE; CONTROLLED STUDY; HEAVY CHAIN; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIC ARTHROPATHY; HUMAN; HUMAN TISSUE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MORPHOLOGY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; SYNOVIUM; TISSUE SECTION; CHEMISTRY; DIAGNOSTIC IMAGING; HEMOPHILIA A; JOINT CAPSULE; MALE; METABOLISM; PATHOPHYSIOLOGY; PROCEDURES; RETROSPECTIVE STUDY;

DIAGNOSTIC IMAGING; FERRITINS; FIBRINOGEN; HEMARTHROSIS; HEMOPHILIA A; HUMANS; JOINT CAPSULE; MALE; PEPTIDE HYDROLASES; RETROSPECTIVE STUDIES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84898863197     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12377     Document Type: Article

References (40)

1. Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 2012; 379: 1447-56.
2. Rodriguez-Merchan EC. Cartilage damage in the haemophilic joints: pathophysiology, diagnosis and management. Blood Coagul Fibrinolysis 2012; 23: 179-83.
3. Roosendaal G, van den Berg HM, Lafeber FP, Bijlsma J. Pathology of synovitis and hemophilic arthropathy. Orthopade 1999; 28: 323-8.
4. Valentino LA. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. J Thromb Haemost 2010; 8: 1895-902.
5. Lafeber FP, Miossec P, Valentino LA. Physiopathology of haemophilic arthropathy. Haemophilia 2008; 14 Suppl 4: 3-9.
6. Melchiorre D, Milia AF, Linari S et al. RANK-RANKL-OPG in hemophilic arthropathy: from clinical and imaging diagnosis to histopathology. J Rheumatol 2012; 39: 1678-86.
7. Seeley EH, Caprioli RM. MALDI imaging mass spectrometry of human tissue: method challenges and clinical perspectives. Trends Biotechnol 2011; 29: 136-43.
8. Schwamborn K, Caprioli RM. MALDI imaging mass spectrometry-painting molecular pictures. Mol Oncol 2010; 4: 529-38.
9. Schone C, Hofler H, Walch A. MALDI imaging mass spectrometry in cancer research: combining proteomic profiling and histological evaluation. Clin Biochem 2013; 46: 539-45.
10. Casadonte R, Caprioli RM. Proteomic analysis of formalin-fixed paraffin-embedded tissue by MALDI imaging mass spectrometry. Nat Protoc 2011; 6: 1695-709.
11. Hardesty WM, Kelley MC, Mi D, Low RL, Caprioli RM. Protein signatures for survival and recurrence in metastatic melanoma. J Proteomics 2011; 74: 1002-14.
12. Pollmann H, Richter H, Ringkamp H, Jurgens H. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur J Pediatr 1999; 158(Suppl 3): S166-70.
13. Lovdahl S, Henriksson KM, Baghaei F et al. Incidence, mortality rates and causes of deaths in haemophilia patients in Sweden. Haemophilia 2013; 19: 362-9.
14. Brackmann HH, Eickhoff HJ, Oldenburg J, Hammerstein U. Long-term therapy and on-demand treatment of children and adolescents with severe haemophilia A: 12 years of experience. Haemostasis 1992; 22: 251-8.
15. Fischer K, van Hout BA, van der Bom JG, Grobbee DE, van den Berg HM. Association between joint bleeds and Pettersson scores in severe haemophilia. Acta Radiol 2002; 43: 528-32.
16. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
17. Valentino LA, Hakobyan N, Enockson C. Blood-induced joint disease: the confluence of dysregulated oncogenes, inflammatory signals, and angiogenic cues. Semin Hematol 2008; 45: S50-7.
18. Bates EJ, Lowther DA, Handley CJ. Oxygen free-radicals mediate an inhibition of proteoglycan synthesis in cultured articular cartilage. Ann Rheum Dis 1984; 43: 462-9.
19. Jansen NW, Roosendaal G, Wenting MJ et al. Very rapid clearance after a joint bleed in the canine knee cannot prevent adverse effects on cartilage and synovial tissue. Osteoarthritis Cartilage 2009; 17: 433-40.
20. de Sousa M, Dynesius-Trentham R, Mota-Garcia F, da Silva MT, Trentham DE. Activation of rat synovium by iron. Arthritis Rheum 1988; 31: 653-61.
21. Roosendaal G, van Rinsum AC, Vianen ME, van den Berg HM, Lafeber FP, Bijlsma JW. Haemophilic arthropathy resembles degenerative rather than inflammatory joint disease. Histopathology 1999; 34: 144-53.
22. Theil EC. Ferritin: structure, gene regulation, and cellular function in animals, plants, and microorganisms. Annu Rev Biochem 1987; 56: 289-315.
23. Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol 2012; 34: 43-62.
24. Degen JL. Hemostatic factors and inflammatory disease. Thromb Haemost 1999; 82: 858-64.
25. Schoenmakers SH, Reitsma PH, Spek CA. Blood coagulation factors as inflammatory mediators. Blood Cells Mol Dis 2005; 34: 30-7.
26. Raghu H, Flick MJ. Targeting the coagulation factor fibrinogen for arthritis therapy. Curr Pharm Biotechnol 2011; 12: 1497-506.
27. Liu X, Piela-Smith TH. Fibrin(ogen)-induced expression of ICAM-1 and chemokines in human synovial fibroblasts. J Immunol 2000; 165: 5255-61.
28. Ho PP, Lee LY, Zhao X et al. Autoimmunity against fibrinogen mediates inflammatory arthritis in mice. J Immunol 2010; 184: 379-90.
29. Flick MJ, LaJeunesse CM, Talmage KE et al. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Investig 2007; 117: 3224-35.
30. Bharadwaj A, Bydoun M, Holloway R, Waisman D. Annexin A2 heterotetramer: structure and function. Int J Mol Sci 2013; 14: 6259-305.
31. Luo M, Hajjar KA. Annexin A2 system in human biology: cell surface and beyond. Semin Thromb Hemost 2013; 39: 338-46.
32. O'Connell PA, Surette AP, Liwski RS, Svenningsson P, Waisman DM. S100A10 regulates plasminogen-dependent macrophage invasion. Blood 2010; 116: 1136-46.
33. Swisher JF, Burton N, Bacot SM, Vogel SN, Feldman GM. Annexin A2 tetramer activates human and murine macrophages through TLR4. Blood 2010; 115: 549-58.
34. Li F, Chung H, Reddy SV et al. Annexin II stimulates RANKL expression through MAPK. J Bone Miner Res 2005; 20: 1161-7.
35. Conus S, Simon HU. Cathepsins: key modulators of cell death and inflammatory responses. Biochem Pharmacol 2008; 76: 1374-82.
36. Sulpizio S, Franceschini N, Piattelli A, Di Sebastiano P, Innocenti P, Selvaggi F. Cathepsins and pancreatic cancer: the 2012 update. Pancreatology 2012; 12: 395-401.
37. Reiser J, Adair B, Reinheckel T. Specialized roles for cysteine cathepsins in health and disease. J Clin Investig 2010; 120: 3421-31.
38. Pozgan U, Caglic D, Rozman B, Nagase H, Turk V, Turk B. Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Biol Chem 2010; 391: 571-9.
39. Bo GP, Zhou LN, He WF et al. Analyses of differential proteome of human synovial fibroblasts obtained from arthritis. Clin Rheumatol 2009; 28: 191-9.
40. Norris JL, Caprioli RM. Analysis of tissue specimens by matrix-assisted laser desorption/ionization imaging mass spectrometry in biological and clinical research. Chem Rev 2013; 113: 2309-42.